Cargando…

The Role of IL-18 in P2RX7-Mediated Antitumor Immunity

Cancer is the leading cause of death worldwide despite the variety of treatments that are currently used. This is due to an innate or acquired resistance to therapy that encourages the discovery of novel therapeutic strategies to overcome the resistance. This review will focus on the role of the pur...

Descripción completa

Detalles Bibliográficos
Autores principales: Janho dit Hreich, Serena, Hofman, Paul, Vouret-Craviari, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252498/
https://www.ncbi.nlm.nih.gov/pubmed/37298187
http://dx.doi.org/10.3390/ijms24119235
_version_ 1785056185479593984
author Janho dit Hreich, Serena
Hofman, Paul
Vouret-Craviari, Valérie
author_facet Janho dit Hreich, Serena
Hofman, Paul
Vouret-Craviari, Valérie
author_sort Janho dit Hreich, Serena
collection PubMed
description Cancer is the leading cause of death worldwide despite the variety of treatments that are currently used. This is due to an innate or acquired resistance to therapy that encourages the discovery of novel therapeutic strategies to overcome the resistance. This review will focus on the role of the purinergic receptor P2RX7 in the control of tumor growth, through its ability to modulate antitumor immunity by releasing IL-18. In particular, we describe how the ATP-induced receptor activities (cationic exchange, large pore opening and NLRP3 inflammasome activation) modulate immune cell functions. Furthermore, we recapitulate our current knowledge of the production of IL-18 downstream of P2RX7 activation and how IL-18 controls the fate of tumor growth. Finally, the potential of targeting the P2RX7/IL-18 pathway in combination with classical immunotherapies to fight cancer is discussed.
format Online
Article
Text
id pubmed-10252498
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102524982023-06-10 The Role of IL-18 in P2RX7-Mediated Antitumor Immunity Janho dit Hreich, Serena Hofman, Paul Vouret-Craviari, Valérie Int J Mol Sci Review Cancer is the leading cause of death worldwide despite the variety of treatments that are currently used. This is due to an innate or acquired resistance to therapy that encourages the discovery of novel therapeutic strategies to overcome the resistance. This review will focus on the role of the purinergic receptor P2RX7 in the control of tumor growth, through its ability to modulate antitumor immunity by releasing IL-18. In particular, we describe how the ATP-induced receptor activities (cationic exchange, large pore opening and NLRP3 inflammasome activation) modulate immune cell functions. Furthermore, we recapitulate our current knowledge of the production of IL-18 downstream of P2RX7 activation and how IL-18 controls the fate of tumor growth. Finally, the potential of targeting the P2RX7/IL-18 pathway in combination with classical immunotherapies to fight cancer is discussed. MDPI 2023-05-25 /pmc/articles/PMC10252498/ /pubmed/37298187 http://dx.doi.org/10.3390/ijms24119235 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Janho dit Hreich, Serena
Hofman, Paul
Vouret-Craviari, Valérie
The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
title The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
title_full The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
title_fullStr The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
title_full_unstemmed The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
title_short The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
title_sort role of il-18 in p2rx7-mediated antitumor immunity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252498/
https://www.ncbi.nlm.nih.gov/pubmed/37298187
http://dx.doi.org/10.3390/ijms24119235
work_keys_str_mv AT janhodithreichserena theroleofil18inp2rx7mediatedantitumorimmunity
AT hofmanpaul theroleofil18inp2rx7mediatedantitumorimmunity
AT vouretcraviarivalerie theroleofil18inp2rx7mediatedantitumorimmunity
AT janhodithreichserena roleofil18inp2rx7mediatedantitumorimmunity
AT hofmanpaul roleofil18inp2rx7mediatedantitumorimmunity
AT vouretcraviarivalerie roleofil18inp2rx7mediatedantitumorimmunity